Drug
Mitapivat clinical trials
Also written AG-348.
- studies test it
- 28
- open now
- 5
- in phase 3
- 11
- first study started
- 2014
Keep track of what changes. Save the mitapivat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
28 studies that test it; most in 2026 (4)
| Year | Studies |
|---|---|
| 2014 | 2 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 10
- Phase 2
- 7
- Phase 3
- 11
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 24 · Other 4
Agios Pharmaceuticals, Inc. (24) · University Health Network, Toronto (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · National Institutes of Health Clinical Center (CC) (1) · EuroBloodNet Association (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses mitapivat is read from its arms, and is right about nine times in ten.
Testing it · 28
- A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat StudyEnrolling by invitationPhase 4Agios Pharmaceuticals, Inc.NCT05777993Written as Mitapivat
- A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)RecruitingPhase 3Agios Pharmaceuticals, Inc.NCT07656415Written as Mitapivat
- A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)RecruitingPhase 3Agios Pharmaceuticals, Inc.NCT07506863Written as Mitapivat
- A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent ThalassemiaRecruitingPhase 3Agios Pharmaceuticals, Inc.NCT07517133Written as Mitapivat
- Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte MembranopathiesNot yet recruitingPhase 2EuroBloodNet AssociationNCT05935202Written as Mitapivat sulfate
- To Assess Safety of Mitapivat and Provide Proof of Concept of the Efficacy of the Drug in Patients With RBC Membranopathies or CDAII.Active, not recruitingPhase 2University Health Network, TorontoNCT07055243Written as Mitapivat
- A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)Active, not recruitingPhase 3Agios Pharmaceuticals, Inc.NCT04770779Written as Mitapivat
- A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension PeriodActive, not recruitingPhase 3Agios Pharmaceuticals, Inc.NCT05144256Written as Mitapivat
- A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)Active, not recruitingPhase 3Agios Pharmaceuticals, Inc.NCT04770753Written as Mitapivat
- A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension PeriodActive, not recruitingPhase 3Agios Pharmaceuticals, Inc.NCT05175105Written as Mitapivat
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of MitapivatActive, not recruitingPhase 1/2National Heart, Lung, and Blood Institute (NHLBI)NCT04610866Written as Mitapivat
- A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)Active, not recruitingPhase 2/3Agios Pharmaceuticals, Inc.NCT05031780Written as Mitapivat
- A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) DeficiencyCompletedPhase 2Agios Pharmaceuticals, Inc.NCT02476916Written as AG-348
- A Study of Mitapivat in Participants With Sickle Cell Disease and NephropathyWithdrawnPhase 2Agios Pharmaceuticals, Inc.NCT06286046Written as Mitapivat
- A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent ThalassemiaActive, not recruitingPhase 2Agios Pharmaceuticals, Inc.NCT03692052Written as AG-348
- Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007CompletedPhase 3Agios Pharmaceuticals, Inc.NCT03853798Written as Mitapivat
- Study of How Mitapivat Affects Midazolam Blood Levels in Healthy ParticipantsCompletedPhase 1Agios Pharmaceuticals, Inc.NCT06648824Written as Mitapivat
- A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic FunctionCompletedPhase 1Agios Pharmaceuticals, Inc.NCT05610657Written as Mitapivat
- A Dose-Finding Study of AG-348 in Sickle Cell DiseaseCompletedEarly Phase 1National Institutes of Health Clinical Center (CC)NCT04000165Written as AG-348
- A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)CompletedPhase 3Agios Pharmaceuticals, Inc.NCT03548220Written as AG-348
See all 28 studies that test mitapivat →
Given in every arm · 1 — mitapivat is usual care beside what is tested
As the comparator · 1 — what is tested is compared with mitapivat
Codes
What other systems call mitapivat · ClinicalTrials.gg INT001174
- MeSH (NLM) C000634504mitapivatConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 2WTV10SIKHMITAPIVATConfirmed FDA, NLM, Wikidata
- RxNorm 2594468One source FDA
- Wikidata Q105337735mitapivatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C157039MitapivatOne source FDA
- DrugBank DB16236One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000634504 | mitapivat | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 2WTV10SIKH | MITAPIVAT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2594468 | — | One source FDA |
| Wikidata | Q105337735 | mitapivat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C157039 | Mitapivat | One source FDA |
| DrugBank | DB16236 | — | One source Wikidata |
Also registered as mitapivat sulfate (UNII N4JTA67V3O · RxNorm 2595574).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.